Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning into a new role and will eventually leave the company as part of the company's strategic simplification. He will transition into the role of senior strategic advisor to CEO Albert Bourla and be less involved in day-to-day operations. The move is likely to reflect continued operational simplification at the company.